Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.42 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191319 | 1.00 | HRH3 (0.48) | HRH3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2266798 | 0.91 | HRH3 (0.51) | HRH3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2267296 | 0.91 | HRH3 (0.51) | HRH3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1787184 | 0.86 | HRH3 (0.51) | HRH3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL2269194 | 0.86 | HRH3 (0.49) | HRH3HRH1CYP2D6 | |
| SCHEMBL2223911 | 0.86 | HRH3 (0.49) | HRH3HRH1CYP2D6 | |
| SCHEMBL6856979 | 0.85 | TP53 (0.39) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1789543 | 0.83 | HRH3 (0.59) | HRH3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1789542 | 0.83 | HRH3 (0.59) | HRH3PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1788302 | 0.83 | HRH3 (0.52) | HRH3PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | claimed |
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| WO-2011083314-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | HRH3, HRH4, HRH2 | HRH3 1/4885PRKAB2 3140/4885PRKAG1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.